Clinical trials: GVHD
GVHD - Graft-Versus-Host Disease
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease
This study is a randomized, double-blind, placebo-controlled, multicenter Phase III trial to compare the efficacy and safety of remestemcel-L-rknd (remestemcel-L), ex-vivo cultured adult human mesenchymal stromal cells (MSC)…
- Trial name
- NCT07568535
- Testing
- Remestemcel-L-rknd
- Volunteers
- 180 people
- Sponsor
- Mesoblast, Ltd.
Breast Cancer, Chronic Myeloproliferative Disorders
Campath-1H + FK506 and Methylprednisolone for GVHD
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00109993
- Testing
- alemtuzumab, methylprednisolone, tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
B-Cell Chronic Lymphocytic Leukemia
Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy
To evaluate whether CAMPATH-1H given to patients with CLL after maximum response to chemotherapy will: a) eliminate minimal residual disease (documented by flow cytometry) in patients who have achieved a complete remission (CR)…
- Trial name
- CRC005 (NCT00800943)
- Testing
- Alemtuzumab (Campath-1H)
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Chronic Lymphocytic Leukemia Research Consortium
Intestinal GVHD, Neutropenic Enterocolitis
Non-invasive Contrast Enhanced Ultrasound Sonography in Intestinal Acute Graft-vs-Host Disease
Intestinal acute graft-vs-host disease (GVHD) is a life-threatening complication after allogeneic hematopoietic cell transplantation. Non-invasive diagnostic procedures are still lacking and diagnosis is difficult.
- Trial name
- NCT01699516
- Where
- Italy
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Pisa
Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease…
- Conditions
- Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT03533816
- Testing
- EAGD T-cell infusion (Phase I), EAGD T-cell infusion (Expansion)
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of Kansas Medical Center
Allogeneic Stem Cell Transplant, Graft Versus Host Disease
Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT)
Retrospective case-note review to determine if nutrition via the enteral compared to the parenteral route results in better outcomes after haematopoietic cell transplantation.
- Conditions
- Allogeneic Stem Cell Transplant, Graft Versus Host Disease, Hematologic Malignancy, Stem Cell Transplant Complications
- Trial name
- NCT03419078
- Volunteers
- 484 people
- Sponsor
- Imperial College Healthcare NHS Trust
Chronic Graft Versus Host Disease
Multiple Donor Treg DLI for Severe Refractory Chronic GVHD
This is a INTERVENTIONAL TRANSPLANTATION STUDY WITHOUT DRUGS. The INTERVENTION is represented by the INFUSION of DONOR T REGULATORY CELL-ENRICHED LYMPHOCYTES to PATIENTS suffering from REFRACTORY CHRONIC GVHD after ALLOGENEIC…
- Trial name
- TREG2015001 (NCT02749084)
- Testing
- T reg DLI
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Mario Arpinati
Chronic Graft vs. Host Disease
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
Background: Chronic graft-versus-host disease (cGVHD) is a multi-organ alloimmune and autoimmune disorder that occurs following allogeneic hematopoietic stem cell transplantation (alloHSCT).
- Trial name
- NCT00092235
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Contrast-enhanced abdominal CT will be performed 1-2 weeks after allogeneic stem cell transplant, and radiographic evidence of mucosal inflammation will be correlated with the subsequent development of acute graft versus host…
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Multiple Myeloma
- Trial name
- GVHD (NCT02117115)
- Testing
- Dynamic contrast-enhanced computed tomography, Ioversol
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Acute Graft-versus-Host Disease
A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD
Evaluate the safety and efficacy of NCR102 injection in the treatment of SR-aGVHD patients who have failed second-line therapy.
- Trial name
- NCT06941350
- Testing
- NCR102 injection
- Volunteers
- 24 people
- Sponsor
- Nuwacell Biotechnologies Co., Ltd.
Cough
The Utility of feNO in the Differential Diagnosis of Chronic Cough
In this study the investigators wish to explore the difference in 24 hr. cough counts measured using the Hull Automated Cough Counter (HACC), from baseline and after two weeks treatment with either montelukast or prednisolone in…
- Trial name
- TUF (NCT02479074)
- Testing
- Montelukast (High FeNO group), Prednisolon, Montelukast (High FeNO), Montelukast (Low FeNO group)
- Where
- United Kingdom
- Volunteers
- 49 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Psoriasis
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to…
- Trial name
- NCT01815424
- Testing
- CP-690,550
- Where
- 24 sites in China, South Korea and 1 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Neck Pain, Cervical Pain
The Effect of Cervical Taping on Neck Pain and Kinematics in Patients With Chronic Neck Pain
Objective: This study examined the effects of elastic tape applied to the neck on patients experiencing chronic neck pain. Background: Neck pain is often persistent or recurrent.
- Conditions
- Neck Pain, Cervical Pain, Chronic Pain
- Trial name
- NCT02915887
- Testing
- Cervical Taping
- Where
- Israel
- Volunteers
- 27 people
- Sponsor
- University of Haifa
Graft-Versus-Host-Disease
Natural History and Pathophysiology of Gastrointestinal Graft-versus-Host Disease
This study will determine the best location to biopsy the gastrointestinal (GI) tract for early and accurate diagnosis of GI graft-versus-host-disease (GVHD).
- Trial name
- NCT00723593
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Graft-versus-host Disease
Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
This is a phase I-II clinical trial. Adult subjects with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they…
- Trial name
- NCT05289167
- Testing
- Cyclophosphamide, Abatacept, Bortezomib
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Northwell Health
cGVHD
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
- Trial name
- THRIVE (NCT05919511)
- Testing
- Non-Interventional
- Where
- 37 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Incyte Corporation
Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
This open-label, Phase I study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of GDC-0853 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
- Trial name
- NCT01991184
- Testing
- GDC-0853
- Where
- 10 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Chronic Graft-versus-host-disease, Leukemia Relapse
A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT
In this study, a randomized, prospective, multicenter, open cohort study was conducted to investigate patients with acute leukemia (14～60-year-old) with different ATG doses (10 mg / kg and 12.5 mg / kg ) in fludarabine, busulfan…
- Trial name
- NCT03190733
- Testing
- ATG
- Volunteers
- 192 people
- Sponsor
- Zhujiang Hospital
Quality of Life, Graft-vs-Host Disease
Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking Vorinostat
Psychological well-being and cognitive function will be measured in patients enrolled on the primary study, NCT01790568, a phase 2 trial of vorinostat plus tacrolimus and methotrexate to prevent graft versus host disease…
- Trial name
- NCT02409134
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sung Choi, M.D.